U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Acalabrutinib

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 1420477-60-6

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of acalabrutinib during breastfeeding. Because acalabrutinib is over 97% bound to plasma proteins, and the half-life of the drug and metabolite are less than 7 hours, the amount in milk is likely to be low. However, the protein binding of the active metabolite is not known and the manufacturer recommends that breastfeeding be discontinued during acalabrutinib therapy and for at least 2 weeks after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Acalabrutinib

CAS Registry Number

1420477-60-6

Drug Class

  • Breast Feeding
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Signal Transduction Inhibitors
  • Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500945PMID: 30000004

Views

Related information

Similar articles in PubMed

  • Review Enasidenib.[Drugs and Lactation Database (...]
    Review Enasidenib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ivosidenib.[Drugs and Lactation Database (...]
    Review Ivosidenib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Axitinib.[Drugs and Lactation Database (...]
    Review Axitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Sonidegib.[Drugs and Lactation Database (...]
    Review Sonidegib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Vismodegib.[Drugs and Lactation Database (...]
    Review Vismodegib.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...